Pyxis Oncology Inc (NASDAQ:PYXS) shares gained 5.91% to $4.12 in overnight trading Tuesday, following the company’s leadership announcement and an upcoming clinical data webcast.
New CEO Brings Track Record Of Major Deals
The Boston-based clinical-stage biopharmaceutical company appointed Thomas Civik, interim CEO since February, as permanent CEO and Chairman, effective Sept. 4. Civik previously led Five Prime Therapeutics through its $1.9 billion acquisition by Amgen Inc (NASDAQ:AMGN) and has also chaired ImCheck Therapeutics and Repare Therapeutics through their respective acquisitions.
Founder John Flavin shifted to Lead Independent Director, according to the announcement, continuing to serve on the board after leading the company since its founding.
Wednesday’s MICVO Data Readout
